Goff 1993.

Methods	Allocation: random, no further details. Blindess: double‐blind. Duration: six weeks. Setting: outpatients, USA. Design: parallel.
Participants	Diagnosis: schizophrenia (31/33), TD (Schooler & Kane). N = 33. Sex: 8F, 20M (5 unclear because of completer analysis). Age: average 48.7 (selegiline), 47.1 (placebo).
Interventions	1. Selegiline (deprenyl): 10 mg/day. N = 17. 2. Placebo. N = 16. Stable neuroleptic medication: dose average (CPE) 549 (selegiline), 683 (placebo).
Outcomes	Leaving the study early. Mental state: BPRS endpoint score. General functioning: GAS endpoint score. Unable to use: adverse effects (not reported).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	No further details.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical capsules given.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No further details.
Incomplete outcome data (attrition bias) All outcomes	High risk	Completer analysis used.
Selective reporting (reporting bias)	Low risk	Main outcomes reported.
Other bias	Low risk	None obvious.